Combined Therapy of CAR-IL-15/IL-15Rα-T Cells and GLIPR1 Knockdown in Cancer Cells Enhanced Anti-tumor Effect Against Gastric Cancer

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Feb 17

PMID 38368374

Authors

Jianbin Ye

Qiaoyuan Liu

Yunxuan He

Zhenkun Song

Bao Lin

Zhiwei Hu

Juanyuan Hu

Yunshan Ning

Cheguo Cai

Yan Li

Affiliations

Soon will be listed here.

Abstract

Background: Chimeric antigen receptor (CAR) T cell therapy has shown remarkable responses in hematological malignancies with several approved products, but not in solid tumors. Patients suffer from limited response and tumor relapse due to low efficacy of CAR-T cells in the complicated and immunosuppressive tumor microenvironment. This clinical challenge has called for better CAR designs and combined strategies to improve CAR-T cell therapy against tumor changes.

Methods: In this study, IL-15/IL-15Rα was inserted into the extracellular region of CAR targeting mesothelin. In-vitro cytotoxicity and cytokine production were detected by bioluminescence-based killing and ELISA respectively. In-vivo xenograft mice model was used to evaluate the anti-tumor effect of CAR-T cells. RNA-sequencing and online database analysis were used to identify new targets in residual gastric cancer cells after cytotoxicity assay. CAR-T cell functions were detected in vitro and in vivo after GLI Pathogenesis Related 1 (GLIPR1) knockdown in gastric cancer cells. Cell proliferation and migration of gastric cancer cells were detected by CCK-8 and scratch assay respectively after GLIPR1 were overexpressed or down-regulated.

Results: CAR-T cells constructed with IL-15/IL-15Rα (CAR-ss-T) showed significantly improved CAR-T cell expansion, cytokine production and cytotoxicity, and resulted in superior tumor control compared to conventional CAR-T cells in gastric cancer. GLIPR1 was up-regulated after CAR-T treatment and survival was decreased in gastric cancer patients with high GLIPR1 expression. Overexpression of GLIPR1 inhibited cytotoxicity of conventional CAR-T but not CAR-ss-T cells. CAR-T treatment combined with GLIPR1 knockdown increased anti-tumor efficacy in vitro and in vivo.

Conclusions: Our data demonstrated for the first time that this CAR structure design combined with GLIPR1 knockdown in gastric cancer improved CAR-T cell-mediated anti-tumor response.

Citing Articles

IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors.

Wickman E, Lange S, Wagner J, Ibanez J, Tian L, Lu M J Immunother Cancer. 2024; 12(11).

PMID: 39572158 PMC: 11580246. DOI: 10.1136/jitc-2024-009743.

Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas.

Mir S, Venugopalan A, Zhang J, Nair N, Sengupta M, Khanal M Clin Transl Med. 2024; 14(11):e70057.

PMID: 39548594 PMC: 11567854. DOI: 10.1002/ctm2.70057.

A New Medical Evaluation for Gastric Cancer Patients to Increase the Success Rate of Immunotherapy: A 2024 Update.

Samasca G, Burz C, Pintea I, Muntean A, Deleanu D, Lupan I Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338286 PMC: 11435362. DOI: 10.3390/ph17091121.

Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder.

Mai Q, He B, Deng S, Zeng Q, Xu Y, Wang C Exp Hematol Oncol. 2024; 13(1):85.

PMID: 39160631 PMC: 11334566. DOI: 10.1186/s40164-024-00553-z.

References

Stoklasek T, Schluns K, Lefrancois L . Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol. 2006; 177(9):6072-80. PMC: 2847275. DOI: 10.4049/jimmunol.177.9.6072. View

Awasthi A, Woolley A, Lecomte F, Hung N, Baguley B, Wilbanks S . Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells. Front Oncol. 2013; 3:225. PMC: 3757444. DOI: 10.3389/fonc.2013.00225. View

Rasmussen L, Frederiksen K, Din N, Galsgaard E, Christensen L, Werner Berchtold M . Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells. Endocr Relat Cancer. 2010; 17(3):809-22. DOI: 10.1677/ERC-09-0326. View

Wu X, Luo H, Shi B, Di S, Sun R, Su J . Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma. Mol Ther. 2019; 27(8):1483-1494. PMC: 6697347. DOI: 10.1016/j.ymthe.2019.04.020. View

Zhang S, Zhao J, Bai X, Handley M, Shan F . Biological effects of IL-15 on immune cells and its potential for the treatment of cancer. Int Immunopharmacol. 2020; 91:107318. DOI: 10.1016/j.intimp.2020.107318. View

Mortier E, Advincula R, Kim L, Chmura S, Barrera J, Reizis B . Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity. 2009; 31(5):811-22. DOI: 10.1016/j.immuni.2009.09.017. View

Guo Y, Luan L, Patil N, Sherwood E . Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev. 2017; 38:10-21. PMC: 5705392. DOI: 10.1016/j.cytogfr.2017.08.002. View

Liu X, Onda M, Watson N, Hassan R, Ho M, Bera T . Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. Proc Natl Acad Sci U S A. 2022; 119(19):e2202439119. PMC: 9171807. DOI: 10.1073/pnas.2202439119. View

Giladi N, Ziv-Av A, Lee H, Finniss S, Cazacu S, Xiang C . RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop. Oncotarget. 2015; 6(26):22680-97. PMC: 4673191. DOI: 10.18632/oncotarget.4205. View

10.

Lawson K, Sousa C, Zhang X, Kim E, Akthar R, Caumanns J . Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature. 2020; 586(7827):120-126. PMC: 9014559. DOI: 10.1038/s41586-020-2746-2. View

11.

Huntington N, Alves N, Legrand N, Lim A, Strick-Marchand H, Mention J . IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci U S A. 2011; 108(15):6217-22. PMC: 3076818. DOI: 10.1073/pnas.1019167108. View

12.

Tian Y, Li Y, Shao Y, Zhang Y . Gene modification strategies for next-generation CAR T cells against solid cancers. J Hematol Oncol. 2020; 13(1):54. PMC: 7236186. DOI: 10.1186/s13045-020-00890-6. View

13.

Park J, Riviere I, Gonen M, Wang X, Senechal B, Curran K . Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):449-459. PMC: 6637939. DOI: 10.1056/NEJMoa1709919. View

14.

Mardiana S, Solomon B, Darcy P, Beavis P . Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Sci Transl Med. 2019; 11(495). DOI: 10.1126/scitranslmed.aaw2293. View

15.

Rubinstein M, Kovar M, Purton J, Cho J, Boyman O, Surh C . Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006; 103(24):9166-71. PMC: 1482584. DOI: 10.1073/pnas.0600240103. View

16.

Zhao M, Luo M, Xie Y, Jiang H, Cagliero C, Li N . Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. Biomed Pharmacother. 2019; 112:108677. DOI: 10.1016/j.biopha.2019.108677. View

17.

Hong M, Clubb J, Chen Y . Engineering CAR-T Cells for Next-Generation Cancer Therapy. Cancer Cell. 2020; 38(4):473-488. DOI: 10.1016/j.ccell.2020.07.005. View

18.

Wrangle J, Velcheti V, Patel M, Garrett-Mayer E, Hill E, Ravenel J . ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018; 19(5):694-704. PMC: 6089612. DOI: 10.1016/S1470-2045(18)30148-7. View

19.

Srour S, Singh H, McCarty J, de Groot E, Huls H, Rondon G . Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020; 135(11):862-865. PMC: 8212349. DOI: 10.1182/blood.2019002920. View

20.

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View